Cargando…
Serotonergic modulation as a pharmacological modality in the treatment of Dravet syndrome
Autores principales: | de Witte, Peter, Lagae, Lieven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445252/ https://www.ncbi.nlm.nih.gov/pubmed/28402511 http://dx.doi.org/10.1093/brain/awx090 |
Ejemplares similares
-
Drug repurposing for Dravet syndrome in scn1Lab
(−/−) mutant zebrafish
por: Sourbron, Jo, et al.
Publicado: (2019) -
Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine
por: Zhang, Yifan, et al.
Publicado: (2015) -
Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
por: Li, Jing, et al.
Publicado: (2021) -
Dravet syndrome: A systematic literature review of the illness burden
por: Strzelczyk, Adam, et al.
Publicado: (2023) -
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe
por: Cardenal‐Muñoz, Elena, et al.
Publicado: (2021)